# Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

> **NCT04328714** · PHASE1 · TERMINATED · sponsor: **Edwin Horwitz** · enrollment: 4 (actual)

## Conditions studied

- Acute Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells

## Key facts

- **NCT ID:** NCT04328714
- **Lead sponsor:** Edwin Horwitz
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-02
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-07-20
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study was suspended pending renovation and reopening of the facility manufacturing the study product, and the study was ultimately terminated in February of 2026.
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04328714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04328714, "Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04328714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*